Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0LO0I
|
|||
| Drug Name |
PMID26560530-Compound-18
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
Stanford University
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H23BrN4O4
|
|||
| Canonical SMILES |
C1C(ON=C1Br)CNC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)OCC4=CC=CC=C4
|
|||
| InChI |
1S/C23H23BrN4O4/c24-21-11-17(32-28-21)13-26-22(29)20(10-16-12-25-19-9-5-4-8-18(16)19)27-23(30)31-14-15-6-2-1-3-7-15/h1-9,12,17,20,25H,10-11,13-14H2,(H,26,29)(H,27,30)/t17?,20-/m0/s1
|
|||
| InChIKey |
MAQVWGRATZCTBU-OZBJMMHXSA-N
|
|||
| CAS Number |
CAS 744198-17-2
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tissue transglutaminase (TG2) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Tissue transglutaminase (TG2) | Target's Patent Info | [1] | |
| KEGG Pathway | Huntington's disease | |||
| Pathway Interaction Database | Beta1 integrin cell surface interactions | |||
| Thromboxane A2 receptor signaling | ||||
| Alpha9 beta1 integrin signaling events | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.